Brendan Bulik-Sullivan

Background

Brendan Bulik-Sullivan is a General Partner at GV specializing in life sciences and therapeutic biotech investments. He holds a BA in mathematics from UC Berkeley and a PhD in statistical genetics from Vrije Universiteit Amsterdam. Prior to GV, he worked at Gritstone Oncology designing ML models for immuno-oncology and at the Broad Institute developing statistical genetics methods. His work has appeared in Nature, Science, and Nature Genetics.

Investment Focus

Notable Investments

Areteia Therapeutics

Respiratory disease biotech

Comanche Biopharma

Cancer metabolism therapy

Ventus Therapeutics

NLRP3 inflammasome inhibitors